GSK is expanding its prospects in hepatology, paying $1.2 billion to acquire a drug that goes after a clinically validated liver target but with a dosing advantage that could give it a competitive ...

GSK announced it has entered a multi-year strategic collaboration agreement with Helix aiming to drive the development of ...

GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a preclinical 30 ...

Following a string of legal wins this year—plus one major setback in May—GSK has washed its hands of yet another lawsuit alleging the once-popular heartburn med Zantac can cause cancer. GSK revealed ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a 2020 licensing agreement. The breakup was initiated by GSK on Dec. 4, Ideaya ...

Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Oct 10 (Reuters) - GSK (GSK.L), ...